Company research / VSTM

Verastem, Inc. (VSTM)

CIK 0001526119 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated MA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Verastem, Inc. reported revenue of $30.91M. Revenue grew 209.1% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $87.53M.

Key ratios (year ended 2025-12-31)

-550.3%
Operating margin
-677.6%
Net margin
-366.2%
Return on year-end equity
209.1%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-12, first reflected in a filing dated 2023-08-08. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$87.53M$30.91M$10.00Mn/a$2.60M$2.05M$88.52M$17.46M$26.72Mn/an/a
Cost of Revenuen/an/an/an/an/an/an/an/a$165.0Kn/an/a
R&D Expense$140.22M$114.60M$81.33M$61.36M$50.56M$39.35M$41.38M$45.78M$43.65M$46.42M$19.78M
Operating Income-$159.80M-$170.13M-$114.96M-$92.08M-$72.94M-$61.41M-$49.36M-$132.34M-$94.78M-$67.80M-$37.00M
Depreciation & Amortizationn/an/an/an/an/an/an/an/an/an/a$670.0K
EBITDAn/an/an/an/an/an/an/an/an/an/a-$36.33M
Net Income-$202.70M-$209.47M-$130.64M-$87.37M-$73.81M-$71.20M-$67.73M-$149.21M-$72.43M-$67.80M-$36.44M
EPS (Diluted)n/a-$3.02-$3.66-$3.96-$4.57-$4.90-$0.44-$2.00-$1.37-$1.76-$0.99
Total Assets$206.51M$246.44M$101.54M$149.72M$95.05M$108.66M$154.35M$145.05M$277.24M$89.79M$83.63M
Total Liabilities$156.53M$189.25M$130.43M$71.19M$47.66M$21.10M$39.08M$137.87M$152.94M$32.11M$11.33M
Long-Term Debtn/an/a$40.72M$40.09M$24.53Mn/an/an/an/a$15.00Bn/a
Shareholders' Equity$49.99M$57.20M-$28.89M$57.37M$47.39M$87.56M$115.27M$7.17M$124.30M$57.68M$72.30M
Cash & Equivalents$136.35M$204.99M$88.82M$77.91M$74.93M$21.25M$67.78M$43.51M$129.87M$82.18M$32.35M
Operating Cash Flow-$162.19M-$137.51M-$104.77M-$86.46M-$63.67M-$53.50M-$33.51M-$138.52M-$74.52M-$57.31M-$29.48M
Capital Expendituresn/an/a$28.0Kn/an/a$196.0K$33.0K$7.0K$1.51Mn/a$39.0K
Free Cash Flown/an/a-$104.80Mn/an/a-$53.70M-$33.54M-$138.53M-$76.02Mn/a-$29.52M
Shares Outstanding90.48M77.74M44.78M25.28M16.71M185.29M170.46M80.12M73.81M50.80M36.99M
Weighted Average Diluted Sharesn/a69.31M35.71M22.05M16.14M14.54M153.33M74.58M69.32M38.42M36.99M
EPS (Basic)n/a-$3.02-$3.66-$3.96-$4.57-$4.90-$0.44-$2.00-$1.12-$1.76-$0.99

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView